<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">AJA</journal-id>
<journal-id journal-id-type="hwp">spaja</journal-id>
<journal-id journal-id-type="nlm-ta">Am J Alzheimers Dis Other Demen</journal-id>
<journal-title>American Journal of Alzheimer's Disease &amp; Other Dementias®</journal-title>
<issn pub-type="ppub">1533-3175</issn>
<issn pub-type="epub">1938-2731</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1533317512464118</article-id>
<article-id pub-id-type="publisher-id">10.1177_1533317512464118</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Letter to the Editor</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Alzheimer’s Disease—Emerging New Potential Therapeutic Modalities</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Kapoor</surname>
<given-names>Shailendra</given-names>
</name>
<xref ref-type="corresp" rid="corresp1-1533317512464118"/>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-1533317512464118">Shailendra Kapoor, 2400 cary street, Mechanicsville, VA 23111, USA Email: <email>shailendrakapoor@yahoo.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>12</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>8</issue>
<fpage>563</fpage>
<lpage>563</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>The recent article by Salloway et al was interesting.<sup>
<xref ref-type="bibr" rid="bibr1-1533317512464118">1</xref>
</sup> Interestingly, a number of new targets have been identified, which may play a potential role in decreasing the cognitive deficits seen in patients with Alzheimer’s disease (AD).</p>
<p>For instance, diosgenin has recently been shown to attenuate the pathological lesions in AD. It does this by activating the 1, 25D (3)-MARRS/Pdia3/ERp57 pathway.<sup>
<xref ref-type="bibr" rid="bibr2-1533317512464118">2</xref>
</sup> Similarly, recent studies indicate that striatal-enriched protein tyrosine phosphatase (STEP) may be involved in the pathogenesis of AD.<sup>
<xref ref-type="bibr" rid="bibr3-1533317512464118">3</xref>
</sup> Modulation of STEP may play a major role in attenuating the risk of AD. Scyllo-inositol is another new agent that decreases neuronal toxicity by promoting low-molecular-weight Aβ and neutralizing Aβ trimers.<sup>
<xref ref-type="bibr" rid="bibr4-1533317512464118">4</xref>
</sup>
</p>
<p>Similarly, recent studies have reported the development of new inhibitors of γ-secretase function that may attenuate the progression of AD.<sup>
<xref ref-type="bibr" rid="bibr5-1533317512464118">5</xref>
</sup> Hsp90 is another prospective target that is being considered for the treatment of AD.<sup>
<xref ref-type="bibr" rid="bibr6-1533317512464118">6</xref>
</sup> α-synuclein is another such potential target.<sup>
<xref ref-type="bibr" rid="bibr7-1533317512464118">7</xref>
</sup>
</p>
<p>The above examples clearly illustrate potential new targets for ameliorating the symptoms of AD and the need for further urgent research to elaborate their potential role in mitigating cognitive decline in patients with AD.</p>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-1533317512464118">
<label>Declaration of Conflicting Interests</label>
<p>The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-1533317512464118">
<label>Funding</label>
<p>The author received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1533317512464118">
<label>1</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Salloway</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mintzer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Geldmacher</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yardley</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mackell</surname>
<given-names>J.</given-names>
</name>
</person-group> <article-title>Subgroup analysis of US and Non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe alzheimer's disease</article-title>. <comment>In press</comment>.</citation>
</ref>
<ref id="bibr2-1533317512464118">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tohda</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Urano</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Umezaki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nemere</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kuboyama</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Diosgenin is an exogenous activator of 1,25D(3)-MARRS/Pdia3/ERp57 and improves Alzheimer's disease pathologies in 5XFAD mice</article-title>. <source>Sci Rep</source>. <year>2012</year>;<volume>2</volume>:<fpage>535</fpage>.</citation>
</ref>
<ref id="bibr3-1533317512464118">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kurup</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nairn</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Lombroso</surname>
<given-names>PJ</given-names>
</name>
</person-group>. <article-title>Striatal-enriched protein tyrosine phosphatase in Alzheimer's disease</article-title>. <source>Adv Pharmacol</source>. <year>2012</year>;<volume>64</volume>:<fpage>303</fpage>–<lpage>325</lpage>.</citation>
</ref>
<ref id="bibr4-1533317512464118">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Thomason</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>McLaurin</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Scyllo-inositol, preclinical, and clinical data for Alzheimer's disease</article-title>. <source>Adv Pharmacol</source>. <year>2012</year>;<volume>64</volume>:<fpage>177</fpage>–<lpage>212</lpage>.</citation>
</ref>
<ref id="bibr5-1533317512464118">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wolfe</surname>
<given-names>MS</given-names>
</name>
</person-group>. <article-title>Gamma-secretase as a target for Alzheimer's disease</article-title>. <source>Adv Pharmacol</source>. <year>2012</year>;<volume>64</volume>:<fpage>127</fpage>–<lpage>153</lpage>.</citation>
</ref>
<ref id="bibr6-1533317512464118">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Michaelis</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Blagg</surname>
<given-names>BS</given-names>
</name>
</person-group>. <article-title>Hsp90 modulation for the treatment of Alzheimer's disease</article-title>. <source>Adv Pharmacol</source>. <year>2012</year>;<volume>64</volume>:<fpage>1</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr7-1533317512464118">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Larson</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Sherman</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Greimel</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Soluble alpha-synuclein is a novel modulator of Alzheimer's disease pathophysiology</article-title>. <source>J Neurosci</source>. <year>2012</year>;<volume>32</volume>(<issue>30</issue>):<fpage>10253</fpage>–<lpage>10266</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>